MedicoX Subsidiary MeCoxCureMed Files IND Application for Oral Anticancer Drug 'Mekbentu' with MFDS
[Asia Economy Reporter Jang Hyowon] MedicoX CureMed, a subsidiary of MedicoX, a KOSDAQ-listed company, announced on the 7th that it has completed the submission of an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety for clinical trials of the oral anticancer drug 'Mecbentu.'
The anticancer drug 'Mecbentu,' for which MedicoX CureMed is initiating clinical trials, is a new drug that changes the administration route by developing Bendamustine, an existing injectable anticancer drug, into an oral form. It primarily targets a wide range of hematologic cancers including follicular lymphoma, lymphocytic leukemia, and multiple myeloma.
According to market research firm Polaris Market Research, the global hematologic cancer treatment market is expected to grow to approximately $87 billion USD (about 107 trillion KRW) by 2025.
MedicoX CureMed applied its proprietary drug delivery platform technology based on the cyclodextrin DDS (Drug Delivery System) in the development process of 'Mecbentu.'
A representative from MedicoX CureMed stated, "Compared to the existing treatment (Bendamustine), which required patient hospitalization for two consecutive days of administration, Mecbentu was developed as the first oral anticancer drug that enhances stability and prolongs half-life through the application of DDS-based drug formulation technology, significantly improving treatment efficacy and convenience. Currently, the indications target hematologic cancers, but we plan to gradually expand development into solid tumors in the future."
The clinical trial, involving Seoul St. Mary's Hospital?ranked among the world's top five hospitals in hematologic cancer?and Yeouido St. Mary's Hospital, will evaluate the drug safety, pharmacokinetic properties, and clinical efficacy of 'Mecbentu' in 30 representative lymphoma patients by comparing it with the existing injectable Bendamustine.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
The company expects that, with the first clinical trial at internationally renowned hospitals in the hematologic cancer field underway, it will be able to accelerate subsequent global clinical trials planned in the United States, Europe, Australia, and other regions. MedicoX CureMed previously began production of 'Mecbentu' for global clinical trials in July through Haupt Pharma Amareg GmbH, a global pharmaceutical manufacturing company based in Germany.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
